Virpax Pharmaceuticals, Inc.
VRPXDelisted Jul 21, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708331
Virpax Pharmaceuticals, Inc. was delisted on Jul 21, 2025; its insiders filed their last Form 4 on Jul 10, 2024; 7 institutions reported holding it in 13F filings for Q1 2025, worth $34.9K in total; no superinvestor held it.
13F holders, Q1 2024
Institutional positions in Virpax Pharmaceuticals, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 6
- −12 vs. Q4 2023
- Shares held
- 1.98K
- −375.3K (−99.5%) vs. Q4 2023
- Total value
- $6.44K
- −$114.1K (−94.7%) vs. Q4 2023
- New holders
- 0
- 0 more added
- Sold out
- 12
- 5 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRPX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $2 |
| Q1 2025 | 7 | $34.9K |
| Q4 2024 | 12 | $46.7K |
| Q3 2024 | 9 | $66.8K |
| Q2 2024 | 8 | $12.6K |
| Q1 2024 | 6 | $6.44K |
| Q4 2023 | 18 | $120.5K |
| Q3 2023 | 13 | $493.4K |
| Q2 2023 | 14 | $827.7K |
| Q1 2023 | 17 | $873.8K |
| Q4 2022 | 21 | $973.0K |
| Q3 2022 | 16 | $2.17M |
| Q2 2022 | 16 | $3.13M |
| Q1 2022 | 16 | $3.29M |
| Q4 2021 | 18 | $7.67M |
| Q3 2021 | 13 | $11.4M |
| Q2 2021 | 7 | $1.12M |
| Q1 2021 | 5 | $1.29M |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Virpax Pharmaceuticals, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Tower Research Capital LLC (TRC) | 1,449 | $6.17K | 0.00% | −4,869−77.1% | Reduced |
| Signature Resources Capital Management, LLC | 500 | $160 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 15 | $64 | 0.00% | −135−90.0% | Reduced |
| Wells Fargo & Company | 8 | $34 | 0.00% | −59−88.1% | Reduced |
| Parallel Advisors, LLC | 1 | $4 | 0.00% | −13−92.9% | Reduced |
| Hantz Financial Services, Inc. | 10 | $0 | 0.00% | −90−90.0% | Reduced |
| The PNC Financial Services Group, Inc. | 0 | $0 | 0.00% | −100,875−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −66,294−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −63,928−100.0% | Sold out |
| Sheets Smith Wealth Management | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −30,500−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −17,734−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −15,221−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −11,695−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −6,616−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −4,358−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −2,400−100.0% | Sold out |
| BlackRock Inc. | 0 | $0 | 0.00% | −464−100.0% | Sold out |